← Back to Search

Procedure

Nerve Block for Total Knee Replacement (CACB Trial)

N/A

Recruiting

Led By Naveed Siddiqui, MD

Research Sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at baseline, 24, 48, 72 hours, seven, 30 and 90 days postoperatively

Awards & highlights

CACB Trial Summary

This trial will assess if using a continuous nerve block during knee replacement surgery can reduce opioid use and improve patients' recovery and quality of life.

Who is the study for?

This trial is for adults over 21 years old who are having a knee replacement in a fast track program and have no drug or alcohol dependency. They must be generally healthy (ASA I-III), not dependent on opioids, without allergies to the study drugs, coagulopathy, low platelets, or issues that prevent catheter placement at the surgery site.Check my eligibility

What is being tested?

The study tests if continuous adductor canal block (CACB) with ropivacaine provides better pain control and recovery compared to a sham procedure (ShACB) using saline after knee replacement surgery. It measures opioid use, quality of recovery scores, pain levels, side effects from opioids, functional status post-surgery, complications related to the nerve block catheter and hospital readmissions.See study design

What are the potential side effects?

Potential side effects may include typical reactions to local anesthetics like ropivacaine such as nausea, vomiting, dizziness or numbness near the injection site. Complications could also arise from catheter placement like infection or bleeding.

CACB Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at baseline, 24, 48, 72 hours, seven, 30 and 90 days postoperatively

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at baseline, 24, 48, 72 hours, seven, 30 and 90 days postoperatively

This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline, 24, 48, 72 hours, seven, 30 and 90 days postoperatively for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

opioid consumption

Secondary outcome measures

Intensity of postoperative pain

Opioid related side effects

Quality of Recovery

CACB Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: CACBActive Control1 Intervention

continuous adductor canal block

Group II: Control groupPlacebo Group1 Intervention

sham continuous adductor canal block - ShACB

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Samuel Lunenfeld Research Institute, Mount Sinai HospitalLead Sponsor

127 Previous Clinical Trials

11,197 Total Patients Enrolled

Naveed Siddiqui, MDPrincipal InvestigatorAssociate Professor

6 Previous Clinical Trials

533 Total Patients Enrolled

Media Library

Continuous Adductor Canal Block (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05962970 — N/A

Total Knee Replacement Research Study Groups: CACB, Control group

Total Knee Replacement Clinical Trial 2023: Continuous Adductor Canal Block Highlights & Side Effects. Trial Name: NCT05962970 — N/A

Continuous Adductor Canal Block (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05962970 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there an ongoing enrollment period for this research?

"The clinicaltrials.gov platform has reported that this trial is not currently looking for participants; the original posting date was on September 1st 2023 and the most recent edit was made on July 26th, 2023. Nevertheless, there are 33 other studies actively seeking patients presently."

Answered by AI